Advertisement
Advertisement
U.S. markets open in 6 hours 52 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Eco Science Solutions, Inc. (ESSI)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.00010.0000 (0.00%)
At close: 02:03PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0001
Open0.0001
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0001 - 0.0001
52 Week Range0.0001 - 0.0125
Volume55
Avg. Volume2,111
Market Cap4,546
Beta (5Y Monthly)-71.06
PE Ratio (TTM)N/A
EPS (TTM)-0.0380
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for ESSI

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • ECO SCIENCE SOLUTIONS INC
    Analyst Report: Exact Sciences CorporationExact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a non-invasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a genetic-based treatment selection test for breast, prostate, and colon cancers. With the acquisitions of Base Genomics and Thrive Earlier Detection, Exact is building a multi-cancer early screening test to detect over 14 cancers, a test that would be one of earliest entrants in multi-cancer liquid biopsy cancer screening.
    Rating
    Fair Value
    Economic Moat
    4 days agoMorningstar
View more
  • We're sorry we weren't able to find anything about this topic.

Advertisement
Advertisement